Developing game changing treatments and cell therapies for severe diseases

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.

MORE ABOUT US

“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”

Professor Ann Logan,
Scientific Director, Neuregenix Ltd.

NEWS

14 June 2019
Information regarding our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital
Since we get several questions about our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska…
Read More
4 March 2019
TFS International AB (TFS) appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Viken – 4th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
8 February 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its…
Read More
6 February 2019
Shadow Lake Group appointed Strategic Advisor and Business Development representative for the licensing process of IBsolvMIR® in Canada
Viken – 6th February 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More

EVENTS

MORE NEWS & EVENTS

SUBSCRIBE